| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/17/2011 | CA2773182A1 Inhibitors of jak |
| 03/17/2011 | CA2773008A1 Transdermal therapeutic system for administering fentanyl or an analogue thereof |
| 03/17/2011 | CA2772989A1 Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer |
| 03/17/2011 | CA2772907A1 Selective antibacterials for clostridium difficile infections |
| 03/17/2011 | CA2772786A1 Compositions of n-benzyl-3-(4-chlorophenyl)-2-[methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]amino]-n-[3-(4-pyridyl)-1-[2-(4-pyridyl)ethyl]propyl]propanamide and uses thereof |
| 03/17/2011 | CA2772697A1 Use of indole derivatives as nurr-1 activators for the application thereof as a medicament for the treatment of parkinson's disease |
| 03/17/2011 | CA2772579A1 Thioimidazolidinone androgen receptor antagonists and uses thereof |
| 03/17/2011 | CA2772525A1 Histamine h3 inverse agonists and antagonists and methods of use thereof |
| 03/17/2011 | CA2772522A1 Histamine h3 inverse agonists and antagonists and methods of use thereof |
| 03/17/2011 | CA2772488A1 Heterocyclic derivatives as inhibitors of glutaminyl cyclase |
| 03/17/2011 | CA2772411A1 Cancer stem cell-targeted and drug resistant cancer therapy |
| 03/17/2011 | CA2772261A1 Novel nucleoside phosphonates and analogs |
| 03/17/2011 | CA2772253A1 Modulators of toll-like receptors |
| 03/17/2011 | CA2772120A1 Use of metformin in cancer treatment and prevention |
| 03/17/2011 | CA2772068A1 Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10) |
| 03/17/2011 | CA2771885A1 1,2-dihydro-2-oxoquinoline compounds as 5-ht4receptor ligands |
| 03/17/2011 | CA2771675A1 Ortho substituted pyrimidine compounds as jak inhibitors |
| 03/17/2011 | CA2771493A1 5-(3, 4-dichloro-phenyl) -n- (2-hydroxy-cyclohexyl)-6-(2,2, 2-trifluoro-ethoxy) -nicotinamide and salts thereof as hdl cholesterol raising agents |
| 03/17/2011 | CA2771452A1 Hsl inhibitors useful in the treatment of diabetes |
| 03/17/2011 | CA2771374A1 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes |
| 03/17/2011 | CA2771172A1 Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
| 03/17/2011 | CA2771124A1 Inhibitors of flaviviridae viruses |
| 03/17/2011 | CA2771099A1 Cancer cell apoptosis |
| 03/17/2011 | CA2770712A1 Heterocyclic compounds as janus kinase inhibitors |
| 03/17/2011 | CA2770554A1 Composition for prevention against spoilage by moulds and yeasts and uses and products related thereto |
| 03/17/2011 | CA2770252A1 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
| 03/16/2011 | EP2295964A1 Irrigation solution |
| 03/16/2011 | EP2295606A1 Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| 03/16/2011 | EP2295604A2 Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features |
| 03/16/2011 | EP2295598A1 Method and kit for detection of cancer, and therapeutic agent for cancer |
| 03/16/2011 | EP2295584A2 Transgenic plant-based methods for plant pests using RNAi |
| 03/16/2011 | EP2295578A2 Cyp1b1 nucleic acids and methods of use |
| 03/16/2011 | EP2295550A2 Crystal structures of GSK-3beta protein and protein complexes and their use. |
| 03/16/2011 | EP2295467A1 Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof |
| 03/16/2011 | EP2295453A2 An appetite-suppressing peptide, its compositions and use |
| 03/16/2011 | EP2295442A2 Inhibitors of interleukin-1beta converting enzyme |
| 03/16/2011 | EP2295441A2 Novel Bicyclonucleoside and Oligonucleotide Analogue |
| 03/16/2011 | EP2295439A1 Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine |
| 03/16/2011 | EP2295437A1 Diazabicyclic central nervous system active agents |
| 03/16/2011 | EP2295436A1 2-Phenyl-subsitituted Imidazotriazinones as Phosphodiesterase V inhibitors |
| 03/16/2011 | EP2295435A1 Substituted porphyrins and their therapeutic use |
| 03/16/2011 | EP2295434A2 Substituted 8-heteroaryl xanthines |
| 03/16/2011 | EP2295433A2 JNK inhibitors |
| 03/16/2011 | EP2295432A1 Process for the preparation of aminobenzimidazole derivatives |
| 03/16/2011 | EP2295431A2 Substantially pure eprosartan free base |
| 03/16/2011 | EP2295430A2 Crystalline solid of eprosartan acetate |
| 03/16/2011 | EP2295429A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases |
| 03/16/2011 | EP2295428A2 Linear pyridazine and pyrrolic compounds, methods of preparation and applications |
| 03/16/2011 | EP2295427A1 Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| 03/16/2011 | EP2295426A1 Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| 03/16/2011 | EP2295424A1 Processes for the preparation of novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase |
| 03/16/2011 | EP2295423A1 Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives |
| 03/16/2011 | EP2295422A2 Glucopyranosyl substituted benzol derivatives, pharmaceutical compositions containing these compounds, use thereof and method for their production |
| 03/16/2011 | EP2295419A2 Substituted tetracycline compounds |
| 03/16/2011 | EP2295418A1 5-(benz-(z)-ylidene)-thiazolidin-4-one derivatives as immunosuppressant agents |
| 03/16/2011 | EP2295417A1 Novel intermediates useful for preparing alpha-(n-sulfonamido)acetamide compound |
| 03/16/2011 | EP2295416A2 Triazole compounds that modulate HSP90 activity |
| 03/16/2011 | EP2295415A1 Quinazoline derivatives |
| 03/16/2011 | EP2295413A1 Indazole compounds useful as protein kinase inhibitors |
| 03/16/2011 | EP2295412A1 Indazole compounds useful as protein kinase inhibitors |
| 03/16/2011 | EP2295410A1 HDAC inhibitor |
| 03/16/2011 | EP2295409A1 Fluoro substituted cycloalkanoindoles and their use as prostaglandin D2 receptor antagonists |
| 03/16/2011 | EP2295408A1 Matrix metalloproteinase inhibitors |
| 03/16/2011 | EP2295406A1 Heterocyclic compound |
| 03/16/2011 | EP2295404A2 Substituted tetracycline compounds |
| 03/16/2011 | EP2295402A2 Antibacterial agents |
| 03/16/2011 | EP2295401A2 Deuterated hepatitis C protease inhibitors |
| 03/16/2011 | EP2295400A2 Process of hydrocyanation of unsaturated carboxylic acid derivatives |
| 03/16/2011 | EP2295392A2 Alkylated aromatic composition for the preparation of carbonated, overbased aromatic sulfonates |
| 03/16/2011 | EP2295081A1 Antibodies to OPGL |
| 03/16/2011 | EP2295063A2 Compositions and the use thereof the treatment of mitochondrial diseases |
| 03/16/2011 | EP2295062A1 The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis |
| 03/16/2011 | EP2295061A1 Agent for treatment of schizophrenia |
| 03/16/2011 | EP2295060A2 Stabilization of hypoxia inducible factor (HIF) alpha |
| 03/16/2011 | EP2295059A2 Stabilization of hypoxia inducible factor (HIF) alpha |
| 03/16/2011 | EP2295058A1 Depot formulations of iloperidone with a polymer |
| 03/16/2011 | EP2295057A1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| 03/16/2011 | EP2295056A1 Use of SNS-595 for treating leukemia |
| 03/16/2011 | EP2295055A2 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of using and compositions thereof |
| 03/16/2011 | EP2295054A1 Ice inhibitors for the treatment of autoinflammatory diseases |
| 03/16/2011 | EP2295053A1 Novel 2H-chromen-2-one-3-carboxamides for medical uses |
| 03/16/2011 | EP2295052A1 Use of ritonavir for improving the pharmacokinetics of drugs metabolized by cytochrome P450 |
| 03/16/2011 | EP2295051A1 Wound healing compound |
| 03/16/2011 | EP2295050A1 Use of agomelatine for the preparation of medicaments for the treatment of sleep disorders in depressed patients |
| 03/16/2011 | EP2295049A1 Treatment of autoimmune diseases |
| 03/16/2011 | EP2295048A1 Synergistic anti-inflammatory pharmaceutical compositions comprising IAA and RIAA |
| 03/16/2011 | EP2295047A2 Use of adenosine A2a receptor antagonists for the treatment of restless leg syndrome and other movement disorders |
| 03/16/2011 | EP2295046A1 Transdermal therapeutic system for application of fentanyl or an analogue material thereof |
| 03/16/2011 | EP2295044A1 Encapsulation using waxy substances |
| 03/16/2011 | EP2295043A1 Controlled release hydrocodone formulations |
| 03/16/2011 | EP2295042A1 Controlled release hydrocodone formulations |
| 03/16/2011 | EP2295041A2 HRT formulations |
| 03/16/2011 | EP2295040A1 Pharmaceutical compositions of pramipexole |
| 03/16/2011 | EP2295038A1 Solid dispersion comprising an anti-HIV agent |
| 03/16/2011 | EP2295037A1 Pharmaceutical formulation containing Ribavirin |
| 03/16/2011 | EP2295036A2 Liquid compositions and methods for treating conditions of the nail unit |
| 03/16/2011 | EP2295035A2 Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (ARB) and neutral endopeptidase (NEP) inhibitor |
| 03/16/2011 | EP2295032A1 Ceramide dispersion |
| 03/16/2011 | EP2295028A1 Preparation for preventing or ameliorating wrinkles, to be taken orally, through injection, or through external application to skin, and cosmetic method |
| 03/16/2011 | EP2294932A1 Carbohydrate mixture and the use thereof for preparing a product for oral or enteral nutrition |